Evidence map›Paper›PMID 24637229›Full record

ArticleNeuro-oncology2014

Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma.

Adam M Sonabend, Arthur S Carminucci, Benjamin Amendolara, Mukesh Bansal, Richard Leung, Liang Lei, Ronald Realubit, Hai Li, Charles Karan, Jonathan Yun and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Adam M SonabendGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Arthur S CarminucciGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Benjamin AmendolaraGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Mukesh BansalGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Richard LeungGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Liang LeiGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Ronald RealubitGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Hai LiGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Charles KaranGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Jonathan YunGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Christopher ShowersGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Robert RothcockGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Jane OGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Andrea CalifanoGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Peter CanollGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
Jeffrey N BruceGabriele Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (A.M.S., A.S.C., B.A., R.L., J.Y., C.S., R.R., J.O, P.C., J.N.B.); Department of Systems Biology, Columbia University, New York, New York (M.B., A.C.); Center for Computational Biology and Bioinformatics, Columbia University, New York, New York (M.B., A.C.); Department of Pathology and Cell Biology, Irving Research Cancer Center, Columbia University Medical Center, New York, New York (L.L.); High Throughput Screening Center, Columbia University Medical Center Judith P. Sulzberger Genome Center, New York, New York (R.R., H.L., C.K.); Department of Biochemistry and Molecular Biophysics, Columbia University Medical Center, New York, New York (A.C.); Department of Biomedical Informatics, Columbia University, New York, New York (A.C.); Institute for Cancer Genetics, Columbia University, New York, New York (A.C.); Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York (A.C.).
High Throughput Biology (United States) · USCancer Genetics (United States) · USColumbia University Irving Medical Center · USColumbia University · US

Funding

Nation Center: Multi-Scale Study- Cellular Networks(RMI)U54CA121852 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2005 to 2015
$37.4M
CHRONIC CONVECTION ENHANCED DELIVERY (CED) OF TOPOTECAN FOR GLIOBLASTOMAR01CA161404 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRUCE, JEFFREY N · 2012 to 2017
$2.9M
Computational analysis of Human High Grade GliomasR01NS061776 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO · 2009 to 2013
$2.4M
The Role of White Matter Progenitors in Glioma Formation and ProgressionR01NS066955 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CANOLL, PETER · 2010 to 2014
$1.7M
NCI NIH HHS 5U54CA121852-09NCI NIH HHS R01 CA161404NINDS NIH HHS 1R01NS066955NINDS NIH HHS 5R01NS061776-05NINDS NIH HHS R01 NS066955
6 · The paper itself

Abstract

backgroundGlioblastoma subtypes have been defined based on transcriptional profiling, yet personalized care based on molecular classification remains unexploited. Topoisomerase II (TOP2) contributes to the transcriptional signature of the proneural glioma subtype. Thus, we targeted TOP2 pharmacologically with etoposide in proneural glioma models.

methodsTOP2 gene expression was evaluated in mouse platelet derived growth factor (PDGF)(+)phosphatase and tensin homolog (PTEN)(-/-)p53(-/-) and PDGF(+)PTEN(-/-) proneural gliomas and cell lines, as well as human glioblastoma from The Cancer Genome Atlas. Correlation between TOP2 transcript levels and etoposide susceptibility was investigated in 139 human cancer cell lines from the Cancer Cell Line Encyclopedia public dataset and in mouse proneural glioma cell lines. Convection-enhanced delivery (CED) of etoposide was tested on cell-based PDGF(+)PTEN(-/-)p53(-/-) and retroviral-based PDGF(+)PTEN(-/-) mouse proneural glioma models.

resultsTOP2 expression was significantly higher in human proneural glioblastoma and in mouse proneural tumors at early as well as late stages of development compared with normal brain. TOP2B transcript correlated with susceptibility to etoposide in mouse proneural cell lines and in 139 human cancer cell lines from the Cancer Cell Line Encyclopedia. Intracranial etoposide CED treatment (680 μM) was well tolerated by mice and led to a significant survival benefit in the PDGF(+)PTEN(-/-)p53(-/-) glioma model. Moreover, etoposide CED treatment at 80 μM but not 4 μM led to a significant survival advantage in the PDGF(+)PTEN(-/-) glioma model.

conclusionsTOP2 is highly expressed in proneural gliomas, rendering its pharmacological targeting by intratumoral administration of etoposide by CED effective on murine proneural gliomas. We provide evidence supporting clinical testing of CED of etoposide with a molecular-based patient selection approach.

Indexed as

AnimalsAntigens, NeoplasmBrain NeoplasmsCell Line, TumorCell SurvivalConvectionDisease Models, AnimalDNA-Binding ProteinsDNA Topoisomerases, Type IIDrug Delivery SystemsEtoposideGlioblastomaHumansMicePoly-ADP-Ribose Binding ProteinsSurvival AnalysisAntigens, NeoplasmDNA-Binding ProteinsDNA Topoisomerases, Type IIEtoposidePoly-ADP-Ribose Binding ProteinsTOP2A protein, humanTop2a protein, mouseTopoisomerase II Inhibitorsconvection-enhanced deliveryetoposidegliomaproneuraltopoisomerase

Identifiers

PMID24637229
PMCPMC4136893
OpenAlexW2099350764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.